Form 4: Akoya Biosciences General Counsel Reports Stock and Option Awards

Jennifer Kamocsay, General Counsel of Akoya Biosciences, reports the acquisition of restricted stock units and stock options, as well as the disposal of shares to cover taxes.

Summary

• On February 22, 2024, Jennifer Kamocsay, General Counsel of Akoya Biosciences, received 35,000 restricted stock units (RSUs) that vest in four equal annual installments starting March 1, 2025.
• Each RSU represents the right to receive one share of Akoya Biosciences common stock.
• On the same date, Kamocsay was granted options to purchase 70,000 shares of Akoya Biosciences common stock at an exercise price of $5.35, with 25% vesting on February 22, 2025, and the remainder vesting in 36 equal monthly installments starting March 22, 2025.
• On March 1, 2024, 3,283 shares were disposed of at a price of $6.03 to cover taxes related to a previous RSU award granted on February 23, 2023.
• Following these transactions, Kamocsay directly owns 99,217 shares of Akoya Biosciences common stock and options to purchase 70,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard equity compensation practices, indicating a stable and incentivized management team. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs and stock options to the General Counsel suggests a continued alignment of interests between management and shareholders.
• The vesting schedules for the RSUs and options incentivize long-term performance and retention.

Negatives

• The disposal of shares to cover taxes, while a common practice, slightly reduces the General Counsel's direct shareholding.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Akoya Biosciences' stock price.
• Changes in tax laws could impact the attractiveness of equity-based compensation.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest a long-term commitment from the General Counsel.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain talent, aligning employee incentives with shareholder value.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in biotech companies like Akoya Biosciences.
• Vesting schedules are generally structured to incentivize long-term commitment, similar to practices at companies like NanoString Technologies and Bio-Techne.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of management's commitment.
• Employees may be motivated by the potential for equity appreciation.

Key Dates